Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for about $1.3 billion. Two of the one-time treatments are in the clinic. Lead candidate VERVE-102, a gene-editing ...

For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.

(NASDAQ:SRPT) plunged to $19.91, down $16.27, or almost 45%, on word of a second death by acute liver failure (ALF) with Elevidys (delandistrogene moxeparvovec), the approved gene therapy for patients ...

Iran has been sending signals to Israel and the U.S. through Arab intermediaries as it looks to de-escalate the conflict and ...

The firm will stop shipping the gene therapy for these patients until a new immunosuppressive regimen is approved for managing acute liver failure.

Wall Street analysts were quick to downgrade Sarepta Therapeutics (NASDAQ:SRPT) on Monday as the company suspended its revenue guidance for 2025 following a second fatality linked to Elevidys, its ...

A second case of acute liver failure (ALF) resulting in the death has been reported in a young recipient of Elevidys ...

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...